Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-LILRB4 + CAR-NK-LILRB4
- Development stage
- Preclinical
- Lead developer
- Immune-Onc Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CART-LILRB4 and CAR-NK-LILRB4 are experimental cell therapies being developed by Immune-Onc Therapeutics to target Leukocyte Immunoglobulin-Like Receptor B4 (LILRB4, also known as ILT3). LILRB4 is an inhibitory immune checkpoint receptor that is highly expressed on the surface of monocytic Acute Myeloid Leukemia (AML) cells and Chronic Myelomonocytic Leukemia (CMML) cells, where it plays a key role in immune suppression and tumor infiltration. These therapies involve engineering T-cells or Natural Killer (NK) cells with chimeric antigen receptors (CARs) that specifically recognize and bind to LILRB4, leading to the targeted destruction of malignant cells. The programs are currently in the discovery or preclinical stages for the treatment of hematologic malignancies.
- Other names
- CAR-T LILRB4CAR-NK LILRB4CART-LILRB4/CAR-NK-LILRB4
02
Targets
LILRB4
Beyond the preview
Go deeper on CART-LILRB4 + CAR-NK-LILRB4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-LILRB4 + CAR-NK-LILRB4.